HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the use of lower doses of busulfan and the
elimination of cyclosporine will further reduce transplant-related side effects for patients
with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or
matched unrelated donors following a preparative regimen of busulfan, fludarabine,
anti-thymocyte globulin and cyclophosphamide.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Fred Hutchinson Cancer Research Center Memorial Sloan Kettering Cancer Center